Cathy McCarty is a partner in Goodwin’s Technology and Life Sciences groups, and a co-chair of Goodwin’s Intellectual Property practice group. Cathy works with clients to protect their innovations and procure intellectual property through intellectual property strategies that are integrated with each client’s business goals. She works with public and private companies of all sizes and stages of development, including venture funded start-ups, venture capital partnerships, and entities that invest in, or evaluate, pharmaceutical and life science companies and technologies.
Cathy specializes in intellectual property relating to pharmaceuticals and general chemistry matters, including small molecule drugs, salt forms, solid forms, and chemical processes. She also has worked on various litigation matters involving pharmaceutical and chemical products.
Cathy approaches each client and each matter with the drive and focus required to master the project at hand. She works to integrate the intellectual property with the practical business issues faced by the client, including scientific, financial, regulatory, and competitive issues. Her client projects are varied and include designing and managing worldwide patent estates on drug candidates, evaluating competitive landscapes to determine patentability and freedom to operate, procuring IP strategy for early stage start-up companies, performing IP due diligence for investors, and advising on license agreements, collaborations, and regulatory issues.
Prior to joining Goodwin in 2017, Cathy was a partner at Lando & Anastasi LLP.
Cathy previously served as a medicinal chemist in drug discovery at Vertex Pharmaceuticals, Abbott Laboratories, and Parke-Davis (now Pfizer); she is an inventor on five issued US Patents.
Harvard Law School
- U.S. Patent and Trademark Office (USPTO)
Recognition & Awards
Cathy has been recognized by The Best Lawyers in America Best Lawyers for her work in Biotechnology and Life Sciences Practice, and Patent Law 2022-2023.
Cathy was a recommended lawyer for Patents: Licensing by The Legal 500 in 2021 and 2022.